- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06295302
A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria
March 5, 2024 updated by: Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Study to Explore the Efficacy, Safety, and Pharmacokinetic Profile of HWH486 in Adults With Chronic Spontaneous Urticaria(CSU)
This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU).
In addition, the pharmacokinetic characteristics will also be investigated.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jie ZHU
- Phone Number: +86 027 87055350
- Email: zhujie@renfu.com.cn
Study Contact Backup
- Name: Yaojun XUE
- Phone Number: +86 027 87055350
- Email: xueyaojun@renfu.com.cn
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China
- Recruiting
- West China Hospital,Sichuan University
-
Contact:
- Bioethics Committee of West China Hospital
- Phone Number: +86 28 8512 3237
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18, ≤70 years old;
- Participants with chronic spontaneous urticaria (CSU) at the time of randomization as defined by the following: presence of itch and hives for ≥ 6 consecutive weeks prior to screening, despite second generation H1-antihistamine during this period; Urticaria Activity Score (UAS7) (range 0-42) ≥16, Hives Severity Score (HSS7) (range 0-21) ≥ 6 and Itch Severity Score (ISS7) (range 0-21) ≥ 6 during 7 consecutive days prior to randomization; CSU duration ≥6 months prior to screening (defined as the onset of CSU as determined by the investigator based on all available supporting documentation).
- Willing and able to complete the Urticaria Participant Daily eDiary (UPDD) for the duration of the study;
- Willing to take background medication and emergency medication according to the study protocol.
6) Written informed consent signed voluntarily by the patient or their legal representatives.
Exclusion Criteria:
- Previous use of HWH486 or other Bruton's tyrosine kinase(BTK) inhibitors;
- Participants having a predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);
- Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
- With symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with a history of gastrointestinal bleeding that is associated with a significant risk of bleeding or coagulopathy, or is clinically significant (such as requiring hospitalization or blood transfusion), or with other chronic medical conditions that are not eligible for participation in this clinical trial, or having a history of malignancy, other than non-metastatic basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of the cervix with appropriate treatment and no signs of recurrence;
- Clinically important laboratory test indicators are abnormal, including: abnormal blood routine: hemoglobin (Hb) < 100g/L, or white blood cell count (WBC) < 3.5×10^9/L; Abnormal liver function: aspartate aminotransferase (AST) ≥1.5×ULN, or alanyl aminotransferase (ALT) ≥1.5×ULN, or total bilirubin (TBIL) ≥1.5×ULN; Abnormal renal function: creatinine (Cr) ≥1×ULN; any other laboratory test indicators that researchers think may affect the evaluation of test results;
- Active and uncontrolled viral and bacterial infections at the time of screening, such as human immunodeficiency virus(HIV), hepatitis B virus(HBV), hepatitis C virus (HCV), syphilis, tuberculosis test results, or if there are any clinical symptoms of bacterial, viral, parasitic or fungal infection requiring treatment;
- Pregnant or breastfeeding women; having pregnancy plans during the clinical trial and within 1 month after the last dose, and do not want to take medically accepted reliable contraceptive methods;
- History of allergy to any investigational therapeutic drug or its excipients;
- History or evidence of alcohol or drug abuse within the six months prior to randomization;
- Use of other immunosuppressive drugs, including but not limited to hydroxychloroquine, methotrexate, cyclosporin A, cyclophosphamide, tacrolimus, mycophenolate, tripterygium, and compound glycyrrhizin, within 30 days or 5 half-lives (whichever is older) prior to screening;
- The investigator determines that the subjects have any conditions that make them unfit to participate in the experiment (such as weak health, poor compliance, etc.).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Matching placebo was administrated orally
|
Experimental: HWH486
|
HWH486 capsule was administrated orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Urticaria Activity Score (UAS) over a 7-day period (UAS7)
Time Frame: Baseline, Week 4
|
Weekly Urticaria Activity Score (UAS7; range 0-42; higher scores reflect greater disease activity)
|
Baseline, Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hive Severity Score (HSS) over a 7-day period (HSS7)
Time Frame: Baseline to Week 4
|
Weekly Hives Severity Score (HSS7; range 0-21; higher scores reflect greater wheals)
|
Baseline to Week 4
|
Change in Itch Severity Score (ISS) over a 7-day period (ISS7)
Time Frame: Baseline to Week 4
|
Weekly Itch Severity Score (ISS7; range 0-21; higher scores reflect greater itching)
|
Baseline to Week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 13, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
February 28, 2024
First Submitted That Met QC Criteria
February 28, 2024
First Posted (Actual)
March 6, 2024
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RFCU-IIa-202308
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Spontaneous Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
Novartis PharmaceuticalsCompletedChronic Spontaneous UriticariaKorea, Republic of, Japan
-
United BioPharmaCompleted
-
United BioPharmaNot yet recruiting
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
United BioPharmaRecruiting
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingChronic Spontaneous UrticariaChina
-
UBP Greater China (Shanghai) Co., LtdNot yet recruitingChronic Spontaneous Urticaria